Integrative Pharmacogenomics Institute (iPROMISE), Universiti Teknologi MARA (UiTM) Malaysia, Puncak Alam, Selangor, Malaysia.
PLoS One. 2013 Aug 23;8(8):e71554. doi: 10.1371/journal.pone.0071554. eCollection 2013.
With a higher throughput and lower cost in sequencing, second generation sequencing technology has immense potential for translation into clinical practice and in the realization of pharmacogenomics based patient care. The systematic analysis of whole genome sequences to assess patient to patient variability in pharmacokinetics and pharmacodynamics responses towards drugs would be the next step in future medicine in line with the vision of personalizing medicine.
Genomic DNA obtained from a 55 years old, self-declared healthy, anonymous male of Malay descent was sequenced. The subject's mother died of lung cancer and the father had a history of schizophrenia and deceased at the age of 65 years old. A systematic, intuitive computational workflow/pipeline integrating custom algorithm in tandem with large datasets of variant annotations and gene functions for genetic variations with pharmacogenomics impact was developed. A comprehensive pathway map of drug transport, metabolism and action was used as a template to map non-synonymous variations with potential functional consequences.
Over 3 million known variations and 100,898 novel variations in the Malay genome were identified. Further in-depth pharmacogenetics analysis revealed a total of 607 unique variants in 563 proteins, with the eventual identification of 4 drug transport genes, 2 drug metabolizing enzyme genes and 33 target genes harboring deleterious SNVs involved in pharmacological pathways, which could have a potential role in clinical settings.
The current study successfully unravels the potential of personal genome sequencing in understanding the functionally relevant variations with potential influence on drug transport, metabolism and differential therapeutic outcomes. These will be essential for realizing personalized medicine through the use of comprehensive computational pipeline for systematic data mining and analysis.
第二代测序技术在测序通量更高、成本更低的情况下,具有将其转化为临床实践和实现基于药物基因组学的患者护理的巨大潜力。对全基因组序列进行系统分析,以评估患者对药物药代动力学和药效学反应的个体间变异性,将是未来医学与个性化医疗愿景一致的下一步。
对一位 55 岁的、自称健康的马来裔匿名男性的基因组 DNA 进行测序。该受试者的母亲死于肺癌,父亲有精神分裂症病史,65 岁去世。开发了一种系统的、直观的计算工作流程/流水线,将定制算法与具有药物基因组学影响的基因变异的大型变体注释和基因功能数据集相结合。使用药物转运、代谢和作用的综合途径图作为模板,映射具有潜在功能后果的非同义变异。
在马来基因组中鉴定出超过 300 万个已知变异和 100,898 个新变异。进一步深入的药物遗传学分析显示,在 563 种蛋白质中共有 607 个独特变异,最终确定了 4 个药物转运基因、2 个药物代谢酶基因和 33 个含有药理学途径中涉及有害 SNV 的靶基因,这些基因可能在临床环境中具有潜在作用。
本研究成功揭示了个人基因组测序在理解具有潜在药物转运、代谢和差异化治疗结果影响的功能相关变异方面的潜力。这些对于通过使用全面的计算管道进行系统的数据挖掘和分析来实现个性化医疗至关重要。